Concordia International Corp. said the U.K. Competition and Markets Authority, or CMA, is investigating the company's international segment as well as certain of its products as part of an inquiry related to the U.K.'s pharmaceutical sector.
The company said that the investigation is at an early, information-gathering stage and the CMA has not reached any conclusions on whether any competition law was infringed.
The company said CMA's investigation includes matters that pre-date Concordia's ownership of Amdipharm Mercury Ltd., the segment in question.